B cells: a new player in mesenchymal stromal cell-mediated immune modulation in renal transplant patients

We read with great interest the B-cell analysis by Erpicum et  al.1 in kidney transplant (KTx) patients, who were infused with third-party mesenchymal stromal cells (MSCs) 2 to 3 days post-KTx. Based on their experience in 10 KTx patients, the investigators reported that there was a decrease in B cells (CD19+) in the MSC-treated group from day 30 (D-30) until D-365. Furthermore, no change in transitional B cells (CD19+CD24+CD38hi) was observed in the MSC-treated group in comparison to the concurrent control subjects.

Source: Kidney International - June 19, 2019 Category: Urology & Nephrology Authors: Urvashi Kaundal, Raja Ramachandran, Amit Arora, Deepesh B. Kenwar, Ratti Ram Sharma, Mukut Minz, Vivekanand Jha, Aruna Rakha Tags: Letter to the Editor Source Type: research